Intracavitary Therapeutics for Pleural Malignancies

Vivek Murthy, Keshav Mangalick, Daniel H. Sterman

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

Original languageEnglish (US)
Pages (from-to)195-209
Number of pages15
JournalClinics in Chest Medicine
Volume39
Issue number1
DOIs
StatePublished - Mar 2018

Keywords

  • Intracavity therapeutics
  • Mesothelioma
  • Pleural malignancies
  • Pleural space

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Intracavitary Therapeutics for Pleural Malignancies'. Together they form a unique fingerprint.

Cite this